Cat. No.: HY-D0184

2'-Deoxycytidine

(Synonyms: Deoxycytidine; Cytosine deoxyriboside; Deoxyribose cytidine)

9 Cited Publications

Customer Review

Based on 9 publication(s) in Google Scholar

2'-Deoxycytidine, a deoxyribonucleoside, can inhibit biological effects of Bromodeoxyuridine (Brdu). 2'-Deoxycytidine is essential for the synthesis of nucleic acids, that can be used for the research of cancer.

For research use only. We do not sell to patients.

Purity: 99.95%
CAS No.: 951-77-9
Formula: C₉H₁₃N₃O₄
Molecular Weight:227.22

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

2'-Deoxycytidine Chemical Structure

CAS No.: 951-77-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (9)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Brdu

Human Endogenous Metabolite

Microbial Metabolite

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
ATH-8 cell line	ED₅₀	>100 μM Compound: 4b	Protection of ATH8 cells against the cytopathic effect of HIV. Protection of ATH8 cells against the cytopathic effect of HIV.	[PMID: 3497272]
C6	IC₅₀	>250 μM Compound: 2'-Deoxycytidine	Cytotoxicity against rat C6 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	10.1039/C3MD00159H
DU-145	IC₅₀	>250 μM Compound: 2'-Deoxycytidine	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	10.1039/C3MD00159H
HaCaT	IC₅₀	>250 μM Compound: 2'-Deoxycytidine	Cytotoxicity against human HaCaT cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as inhibition of cell viability after 48 hrs by MTT assay	10.1039/C3MD00159H
HCT-116	EC₅₀	>10 μM Compound: 5azadC	Antiproliferative activity against human HCT116 cells after 2 to 4 days by ATPlite 1step luminescence assay Antiproliferative activity against human HCT116 cells after 2 to 4 days by ATPlite 1step luminescence assay	[PMID: 26220519]
KARPAS-299	EC₅₀	>0 μM Compound: 5azadC	Antiproliferative activity against human KARPAS299 cells after 2 to 4 days by ATPlite 1step luminescence assay Antiproliferative activity against human KARPAS299 cells after 2 to 4 days by ATPlite 1step luminescence assay	[PMID: 26220519]
KG-1	EC₅₀	0.1 μM Compound: 5azadC	Antiproliferative activity against human KG1 cells after 2 to 4 days by ATPlite 1step luminescence assay Antiproliferative activity against human KG1 cells after 2 to 4 days by ATPlite 1step luminescence assay	[PMID: 26220519]
L6	IC₅₀	>250 μM Compound: 2'-Deoxycytidine	Cytotoxicity against rat L6 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against rat L6 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	10.1039/C3MD00159H
MCF7	IC₅₀	>250 μM Compound: 2'-Deoxycytidine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	10.1039/C3MD00159H

In Vivo

2'-Deoxycytidine (25 mg/kg, i.v., 4 times, from 8 days to 16 days) inhibits tumor growth in mice inoculated SP2/0 myeloma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice inoculated SP2/0 myeloma cells^[2]
Dosage:

25 mg/kg
Administration:

i.v., 4 times, from 8 days to 16 days
Result:

Decreased the tumor weight and volume.
Increased survival time.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 951-77-9
Appearance Solid
Molecular Weight 227.22
Formula C₉H₁₃N₃O₄
Color White to off-white
SMILES

O=C1N([C@H]2C[C@H](O)[C@@H](CO)O2)C=CC(N)=N1
Synonyms

Deoxycytidine; Cytosine deoxyriboside; Deoxyribose cytidine
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (9)

All

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Int J Biol Macromol

Crude polysaccharide from Danggui Buxue decoction enhanced the anti-tumor effect of gemcitabine by remodeling tumor-associated macrophages. [Abstract]

2023 Jul 1;242(Pt 4):125063. PMID: 37245770
Cell Rep

SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. [Abstract]

2020 May 12;31(6):107640. PMID: 32402273
Anal Chem

Ultrahigh Flow Regulated Discharge Coupling with Targeted Mass Spectrometry Analysis: Real Time Capturing Biomolecules in Exhaled Breath. [Abstract]

2025 May 13;97(18):9827-9835. PMID: 40302637
JCI Insight

Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism. [Abstract]

2022 Nov 22;7(22):e159419. PMID: 36227698
Food Biosci

2025 Jun.
Clin Epigenetics

Methylation silencing of TGF-β receptor type II is involved in malignant transformation of esophageal squamous cell carcinoma. [Abstract]

2020 Feb 11;12(1):25. PMID: 32046777
J Pharm Biomed Anal

A novel UHPLC-MS/MS approach for simultaneous quantification of pyrimidine metabolites in human biofluids. [Abstract]

2025 Nov 15:265:117026. PMID: 40544701
Research Square Preprint

2021 May.

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (440.10 mM; Need ultrasonic)

DMSO : 50 mg/mL (220.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.4010 mL

22.0051 mL

44.0102 mL

5 mM

0.8802 mL

4.4010 mL

8.8020 mL

10 mM

0.4401 mL

2.2005 mL

4.4010 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (11.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 110 mg/mL (484.11 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Horn D, et al. Inhibition of biological effects of bromodeoxyuridine by deoxycytidine: correlation with decreased incorporation of bromodeoxyuridine into DNA. Somatic Cell Genet. 1976 Sep;2(5):469-81. [Content Brief]

[2]. Iwazaki A, et al. Intravenously administered 2'-deoxycytidine suppresses mouse myeloma tumor growth. Biol Pharm Bull. 2012;35(2):251-5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	4.4010 mL	22.0051 mL	44.0102 mL	110.0255 mL
	5 mM	0.8802 mL	4.4010 mL	8.8020 mL	22.0051 mL
	10 mM	0.4401 mL	2.2005 mL	4.4010 mL	11.0026 mL
	15 mM	0.2934 mL	1.4670 mL	2.9340 mL	7.3350 mL
	20 mM	0.2201 mL	1.1003 mL	2.2005 mL	5.5013 mL
	25 mM	0.1760 mL	0.8802 mL	1.7604 mL	4.4010 mL
	30 mM	0.1467 mL	0.7335 mL	1.4670 mL	3.6675 mL
	40 mM	0.1100 mL	0.5501 mL	1.1003 mL	2.7506 mL
	50 mM	0.0880 mL	0.4401 mL	0.8802 mL	2.2005 mL
	60 mM	0.0734 mL	0.3668 mL	0.7335 mL	1.8338 mL
	80 mM	0.0550 mL	0.2751 mL	0.5501 mL	1.3753 mL
	100 mM	0.0440 mL	0.2201 mL	0.4401 mL	1.1003 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

2'-Deoxycytidine

9 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

2'-Deoxycytidine

FDA Approved & Pharmacopeial Drug Library

Anti-Blood Cancer Compound Library

Microbial Metabolite Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Nucleotide Metabolite Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) 2'-Deoxycytidine

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (9)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

2'-Deoxycytidine Related Classifications

HY-D0184 Related Classifications